Latest news with #UltragenyxPharmaceutical
Business Insider
15-05-2025
- Business
- Business Insider
Bank of America Securities Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $80.00. The company's shares closed yesterday at $34.72. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Ahmad is an analyst with an average return of -5.3% and a 43.00% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. In addition to Bank of America Securities, Ultragenyx Pharmaceutical also received a Buy from Morgan Stanley's Maxwell Skor in a report issued on May 8. However, on May 7, Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical (NASDAQ: RARE). RARE market cap is currently $3.41B and has a P/E ratio of -6.02. Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year. Earlier this month, Eric Crombez, the EVP and Chief Medical Officer of RARE sold 242.00 shares for a total of $8,496.62.
Yahoo
08-05-2025
- Business
- Yahoo
Ultragenyx price target lowered to $100 from $140 at Truist
Truist lowered the firm's price target on Ultragenyx (RARE) to $100 from $140 and keeps a Buy rating on the shares. The company's Q1 results were in-line and the management reiterated its FY25 revenue guidance, though the firm's price target is cut on tampered outlook for gene therapy programs, the analyst tells investors in a research note. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on RARE: Disclaimer & DisclosureReport an Issue Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point Investors will be rewarded for buying Ultragenyx at $35, says Citi Buy Recommendation for Ultragenyx Pharmaceutical Driven by Strong Commercial Execution and Promising Pipeline Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
